publié le 23 février 2022

L’efficacité de la thérapie au laser pour le traitement de la mucite buccale sévère induite par la chimiothérapie chez l’enfant

Multicenter randomized, double-blind controlled trial to evaluate the efficacy of laser therapy for the treatment of severe oral mucositis induced by chemotherapy in children : laMPO RCT

PMID: 29727048 DOI: 10.1002/pbc.27098

https://pubmed.ncbi.nlm.nih.gov/29727048/

 

Abstract

 

Objectives

To demonstrate the efficacy of laser photobiomodulation (PBM) compared to that of placebo on severe oral mucositis (OM) in pediatric oncology patients. The primary objective was the reduction of OM grade (World Health Organization [WHO] scale) 7 days after starting PBM. Secondary objectives were reduction of pain, analgesic consumption, and incidence of side effects.

 

Methods

One hundred and one children with WHO grade > 2 chemotherapy-induced OM were enrolled in eight Italian hospitals. Patients were randomized to either PBM or sham treatment for four consecutive days (days +1 to +4). On days +4, +7, and +11, OM grade, pain (following a 0-10 numeric pain rating scale, NRS) and need for analgesics were evaluated by an operator blinded to treatment.

 

Results

Fifty-one patients were allocated to the PBM group, and 50 were allocated to the sham group. In total, 93.7% of PBM patients and 72% of sham patients had OM grade < 3 WHO on day +7 (P = 0.01). A significant reduction of pain was registered on day +7 in the PBM versus sham group (NRS 1 [0-3] vs. 2.5 [1-5], P < 0.006). Reduced use of analgesics was reported in the PBM group, although it was not statistically significant. No significant adverse events attributable to treatment were recorded.

 

Conclusions

PBM is a safe, feasible, and effective treatment for children affected by chemotherapy-induced OM, as it accelerates mucosal recovery and reduces pain.

 

Keywords

clinical trial; laser; mucositis; pediatric hemato-oncology; supportive care.


Vous avez aimé cet article ? Partagez le !

Des études qui pourraient vous intéresser

Vous avez des questions, contactez-nous !

Fusion entre K-LASER et INDIBACommuniqué de presse

INDIBA S.A et Eltech K-laser S.r.l, deux experts de l’innovation et leaders mondiaux dans leurs domaines respectifs unissent leurs forces pour un avenir commun et de nouvelles opportunités mondiales.